UPM Raflatac pharma labelling with foresight at Pharmapack 2017

UPM Raflatac's pharmaceutical labelling experts will be present at Pharmapack 2017 on 1-2 February 2017. Visitors to stand J11 will have the opportunity to see and discuss up-to-the-minute labelling solutions specified for the latest market needs.

In particular, UPM Raflatac will be focusing on a range of materials designed to meet the 2019 deadline for compliance with the Falsified Medicines Directive. The RP62 EU adhesive secures the supply chain from counterfeits by creating cardboard tear as a means of tamper-verification on cardboard pharmaceutical packs. RP62 EU is available with paper and film label options. By integrating with existing pack designs, few solutions offer the same ease of adoption.

Also highlighted will be the new Pharmaclear EUP label film. Pharmaclear EUP meets European Pharmacopoeia requirements stipulated in Monograph 3.1.4 regarding polyolefins. It is also compliant to FDA 177.1520 and regulation (EU) No 10/2011 on plastic materials and articles intended to come into contact with food.

"Medicinal products in plastic containers are at risk from the leaching of chemical constituents from primary and secondary packaging and labels. Pharmaclear EUP combined with the low-leachables RP31 Purus meets pharmaceutical requirements for patient safety through comprehensive regulatory compliance," comments Michael Pilastro, Business Development Manager, Pharma, UPM Raflatac EMEIA.

"Suitable for labelling small diameters and sterilization by steam autoclave, EtO, gamma and e-irradiation, the Pharmaclear EUP and RP31 Purus combination is applicable across a broad range of pharmaceutical and healthcare applications. This introduces a great deal of efficiency to the extractable and toxicological studies conducted by brand owners, with the assurance of providing the safest possible labelling solution with a high degree of indemnity."

UPM Raflatac welcomes visitors to Pharmapack 2017 at stand J11, hall 4.